Ocular Therapeutix

IPO

Transforming Retinal Disease Treatment with AXPAXLI™

Public · Bedford, United States · Founded 2006 · $836.7M raised

Employees
201–500
Founded
2006
Business Model
B2B
Website
ocutx.com
Total Funding
$836.7M
Last Round
$475.0M Private EquitySep 2025
Rounds
8
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Ocular Therapeutix develops sustained-release therapies for retinal disease using its proprietary, bioresorbable ELUTYX hydrogel platform. Its lead program, AXPAXLI, delivers axitinib by intravitreal injection and is being investigated for wet age-related macular degeneration and nonproliferative diabetic retinopathy. The platform supports localized drug delivery intended to maximize therapeutic efficacy while minimizing systemic exposure.

Summary

Ocular Therapeutix is a Biotech company based in Bedford, United States, founded in 2006. It has raised $836.7M in total across 8 rounds, most recently a $475.0M Private Equity round in Sep 2025. Investors include Ascension Health and Polaris Partners.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Private EquityPrivate EquitySep 2025
$475.0M

Sign up to see all 9 events

Funding: Seed through Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ocular Therapeutix on Indexed.vc
<a href="https://indexed.vc/companies/ocular-therapeutix"><img src="https://indexed.vc/api/badge/company/ocular-therapeutix" alt="Ocular Therapeutix on Indexed.vc" width="260" height="76" /></a>